Logo Image

Hossein Borghaei, DO, Fox Chase Cancer Center

Articles by Hossein Borghaei, DO, Fox Chase Cancer Center

Emerging Treatments in SCLC: Bispecific Antibodies

ByHossein Borghaei, DO, Fox Chase Cancer Center,Anne Chiang, MD, PhD, Yale Cancer Center,Wade Iams, MD, Vanderbilt University Medical Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Vivek Subbiah, MD, MD Anderson Cancer Center

Expert panelists weigh in on emerging data from recent presentations on small cell lung cancer, including novel immunotherapy approaches such as bispecific antibodies targeting DLL3 or therapies targeting TIGIT.

First-Line Therapy in ES SCLS: KEYNOTE-604

ByHossein Borghaei, DO, Fox Chase Cancer Center,Anne Chiang, MD, PhD, Yale Cancer Center,Wade Iams, MD, Vanderbilt University Medical Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Vivek Subbiah, MD, MD Anderson Cancer Center

Key opinion leader in lung cancer, Vivek Subbiah, MD, examines the phase 3 KEYNOTE-604 trial of platinum-based chemotherapy + pembrolizumab and considers whether the data support findings from other trials of chemotherapy + IO combination approaches.

Latest Updated Articles